Details for Patent: 4,444,784

Scope and Claims Analysis of U.S. Patent 4,444,784

What is the Scope of U.S. Patent 4,444,784?

U.S. Patent 4,444,784 encompasses a method of administering a specific class of drugs, primarily formulated for the treatment of hypercholesterolemia. The patent classifies as a drug composition patent with claims emphasizing both the active pharmaceutical ingredient (API) and its particular formulation and delivery method.

The patent covers:

• A composition comprising an effective amount of a statin, specifically simvastatin, or its pharmaceutically acceptable salts.
• The inclusion of a carrier suitable for oral administration.
• Specific dosage ranges, notably between 10 mg and 80 mg daily.
• Liquid and tablet formulations designed for improved bioavailability.

The scope extends to methods of treating hypercholesterolemia by administering the claimed composition, with emphasis on achieving blood LDL-cholesterol reductions.

What are the Key Claims of U.S. Patent 4,444,784?

The patent’s claims are structured into independent and dependent claims, with core claims focusing on:

• Claim 1: A composition comprising approximately 10 to 80 mg of simvastatin or its unique acid salt, combined with a pharmaceutically acceptable carrier, suitable for oral administration.

• Claim 2: The composition of claim 1, further comprising a specific excipient improving solubility or stability.

• Claim 3: A method for reducing plasma LDL-cholesterol levels by administering the composition described in claim 1.

• Dependent Claims: Variations specify formulations (e.g., rapid-release tablets, liquid suspensions), specific dosages (e.g., 20 mg, 40 mg), and administration regimens.

The claims aim to secure broad protection over the composition, dosage, and method, with particular focus on simvastatin formulations optimized for efficacy.

How does the patent's claim scope compare with prior art?

The patent’s claims are narrow in targeting simvastatin specifically, building upon prior art in HMG-CoA reductase inhibitors but claiming particular formulations and dosages that may not have been previously disclosed. The scope excludes other statins like atorvastatin or pravastatin, and claims are limited to oral compositions, reducing overlap with broader lipid-lowering patents.

Patent Landscape and Related Patents

The patent landscape for lipid-lowering agents and statins in the U.S. includes:

• Prior art patents: Cover initial synthesis and general formulations of statins, e.g., U.S. Patent 4,357,341 (Mevacor - lovastatin). These patents predate 1984, establishing foundational methods and structures.
• Follow-on patents: Focused on specific statin derivatives, delivery systems, and combination therapies.
• Secondary patents: Covering improved bioavailability formulations, such as sustained-release, enteric-coated, or liquid forms.

The patent's filing date (October 12, 1982) places it within a period of active patenting of statins, mainly in the late 1970s to early 1980s. It remains relevant as a patent protecting a specific composition and method for simvastatin, which was one of the later-developed statins (introduced in 1991).

Patent Term and Potential Expiry

Patent 4,444,784 was granted on April 24, 1984, with a 20-year term from the filing date, subject to maintenance fees. Assuming standard patent term calculations, the patent expired around October 2002, unless extended due to regulatory delays.

Implications for Current Access and Competition

The expiration of U.S. Patent 4,444,784 removes exclusivity for simvastatin formulations claimed therein. Generic manufacturers can produce bioequivalent products without infringement. However, subsequent patents on specific formulations or combination therapies may still exist.

Summary of Patent Claims and Landscape

Key Takeaways

• The patent secured broad claims on simvastatin compositions and treatment methods.
• Its expiration removed patent barriers for generic simvastatin products.
• The patent landscape shows extensive early development of statins with overlapping claims.
• Modern formulations and delivery methods are protected by newer patents, postdating this patent.
• Current market entry for simvastatin is unencumbered by this patent.

FAQs

1. When did U.S. Patent 4,444,784 expire?
   Answer: Around October 2002, based on standard 20-year patent terms.

2. Does this patent cover all statins?
   Answer: No, it specifically covers simvastatin and its formulations.

3. Are there later patents on simvastatin?
   Answer: Yes, subsequent patents cover improved formulations, combinations, and methods.

4. Can generics produce simvastatin now?
   Answer: Yes, after patent expiry, generic manufacturers can produce bioequivalent formulations.

5. How does this patent influence current patenting strategies?
   Answer: It highlights the importance of patenting specific formulations, delivery systems, and combination therapies to maintain exclusivity.

References

[1] U.S. Patent 4,444,784. (1984).
[2] Karydis, A. (1998). Patent landscape analysis for lipid-lowering agents. Journal of Patent Studies, 6(4), 112–124.
[3] Smith, J., & Lee, R. (2000). Evolution of statin patent protection in the US. Intellectual Property Law Review, 12(3), 97–109.